Th183 - The Futuristic Cure of Type 1 Diabetes

Abstract Text: Problem: Type 1 Diabetes is an autoimmune disease where Beta cells are destroyed resulting in life long dependency on insulin therapy and blood sugar monitoring. At the terminal end of the disease spectrum of Type 1 Diabetes— when there is already a substantial damage to multiple organs such as in eyes and kidneys, the patient is offered Islet cell transplant as a potential cure for Type 1 Diabetes. The cure in fact is traded with iatrogenic complications by introducing immune suppressive drugs to preserve functioning of fragile islet cells. The immune suppression of the host expose him to increased risk of infection and cancers. Islet cells often don’t survive long enough. This requires repeated islet cell infusion potentially in portal veins that contribute to adverse effects such as Induction of instant Blood-Mediated Inflammatory Reactions (IBMIR). This happens as a result of activation of thrombosis and complement pathways. This is the sole reason for post-transplantation islet loss with its adverse effects.
Solution: New approach to cure Type 1 Diabetes and its vascular complications are based on targeting amplifying loop of C3 that control 80% of complement activation that cause immune pathogenesis of Type 1 diabetes and islet cell transplant failures.
Endocrine Technology has developed a small molecule that targets immune- inflammatory aspects of Type 1 diabetes. Appropriate formulation and clinical trials are needed for futuristic cure of Type 1 Diabetes.